Concord Drugs Limited held its 31st Annual General Meeting (AGM) for the financial year 2025-26 on September 30, 2026. The meeting was conducted via video conference, concluding at 9:50 am after all seven proposed resolutions were approved by shareholders.

The agenda included the adoption of audited standalone and consolidated financial statements, reappointment of directors, and approval of related party transactions for FY27. Scrutinizer P Srikant Kumar of PSK & Associates confirmed that no invalid votes were recorded across any resolution.

Voting participation and turnout

A total of 4,482 shareholders were on record as of September 23, 2026. Participation was primarily through remote e-voting and video conferencing. While no shareholders attended in person or through proxy, 63 individuals participated via video conferencing. The voting results indicate a high concentration of support, with promoters holding 59,39,204 shares casting 100% votes in favor for every resolution.

Public non-institutional shareholders held 72,35,796 shares but polled only 4,38,637 votes. Of these, 4,38,631 votes were cast in favor, while 6 votes were against. This resulted in an overall approval rate of 99.9999% across all seven items on the agenda.

Resolutions approved

The following ordinary and special resolutions were passed:

• Adoption of audited standalone and consolidated financial statements for FY26.
• Reappointment of Mr. S. Nagi Reddy as a director retiring by rotation.
• Reappointment of statutory auditors for a second five-year term.
• Approval of related party transactions for FY27.
• Ratification of remuneration for cost auditors M/S. KJU & Associates for FY27.
• Reappointment of Mr. S. Nagavenkata Hareesh Kumar Solleti as an independent director (Special Resolution).
• Reappointment of Ms. Sumeela Kasu as an independent director (Special Resolution).

What the numbers show

The voting data reveals a stark divergence between promoter and public shareholder engagement. Promoters exercised 100% of their holding's voting rights, whereas public non-institutional holders utilized only 6.062% of their total shareholding to vote. Despite this low turnout from the public float, the negligible dissent of just 6 shares against each resolution suggests strong alignment with management proposals among participating minority shareholders.

Concord Drugs board approved the company’s audited standalone and consolidated financial statements for FY26 during a meeting held on September 7, 2026. The directors also approved the notice for the 31st Annual General Meeting (AGM), scheduled to take place via video conferencing on September 30, 2026.

The board set the record date for remote e-voting eligibility as September 23, 2026. The register of members and share transfer books will remain closed from September 24 to September 30, 2026, both days inclusive.

Governance and Appointments

The board proposed the re-appointment of S. Nagi Reddy, Chairman and Managing Director, who retires by rotation at the ensuing AGM. Reddy holds 30,60,536 equity shares in the company and has approximately 28 years of experience in the pharmaceutical industry.

Two independent directors were also recommended for re-appointment for second terms of five consecutive years:

• S. Nagavenkata Hareesh Kumar Solleti, subject to member approval
• Sumeela Kasu, with a term commencing June 1, 2027, to May 31, 2032

Auditor and Transaction Approvals

Based on the Audit Committee’s recommendation, the board approved the re-appointment of Pundarikashyam and Associates as statutory auditors for five consecutive years. The proposed remuneration is ₹4,00,000 per annum, plus applicable taxes and reimbursement of reasonable out-of-pocket expenses.

The board also sought member approval for material related-party transactions proposed for FY27, stating these would be undertaken in the ordinary course of business on an arm’s-length basis. Additionally, the remuneration of KJU & Associates, appointed as cost auditors for FY27, requires ratification by members.

What the Numbers Show

The filing focuses on procedural governance rather than operational performance metrics. With no revenue, profit, or order inflow data disclosed in this specific board outcome notice, the primary signal is continuity in leadership and audit oversight, ensuring stability in corporate governance for the upcoming fiscal year.